ARGATROBAN

Post-LOE

argatroban

Gland Pharma

ANDAINJECTIONINJECTABLE

Approved

Jan 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ARGATROBAN (argatroban) by Gland Pharma is thrombin inhibitors [moa]. Approved for for prophylaxis or treatment of thrombosis. First approved in 2021.

Drug data last refreshed 18h ago

Mechanism of Action

Thrombin Inhibitors

Pharmacologic Class:

Anti-coagulant

Indications (1)

For prophylaxis or treatment of thrombosis

Clinical Trials (2)

NCT01246011Phase 4Terminated

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

Started Nov 2010

9 enrolled

Coronary Artery Bypass Graft SurgeryPresence of Heparin/Platelet Factor 4 Antibody

NCT00039858Phase 4Completed

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

Started Sep 2003

24 enrolled

ThrombocytopeniaThrombosis

Worked on ARGATROBAN at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.